Samsung Biologics' decision to split its business was postponed to Oct. 17
Aug 22, 2025
|
Samsung Biologics announced on the 22nd that it will change the shareholders' meeting date to approve the split plan from September 16 to October 17.
It was planned to submit a securities report on the 29th of last month, but the shareholders' meeting date was also postponed as the submission of the report was delayed by about a month due to the request of the stock exchange.
On the 21st, the Korea Exchange's Securities Market Headquarters decided to be eligible as a result of a preliminary review of Samsung Biologics' division and relisting.
Samsung Biologics will restate its subsidiary management and new investment business division as Samsung Epis Holdings. Samsung Epis Holdings, which will be newly established as a pure holding company, will incorporate biosimilar company Samsung Bioepis as a complete subsidiary in the future, and will establish a new subsidiary in November. Samsung Epis Holdings will be reorganized into a 100% subsidiary of Samsung Bioepis and a company planned to be established in the future, while Samsung Biologics will have only Samsung Biologics America as a subsidiary.
Meanwhile, due to the postponement of the shareholders' meeting, the scheduled founding date of Samsung Epis Holdings has also been changed from October 1 to early November. However, the changed division date, November 1, is Saturday, so November 3rd, when applying for registration, is expected to be the actual establishment date.
The scheduled date for the change of Samsung BioLogics' listing and the re-list of Samsung Epis Holdings, a new company, has been changed from Oct. 29 to Nov. 24.
This article was translated by Naver AI translator.
